Anna Praidou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Praidou has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Sofia Androudi
University of Thessaly
7 shared publications Periklis Brazitikos
Department of Ophthalmology, Aristotle University, 54124 Thessaloniki, Greece
5 shared publicationsEleni Papakonstantinou
Department of Pharmacology, School of Medicine, Aristotle University, 54124 Thessaloniki, Greece
4 shared publicationsGeorge Karakiulakis
2nd Department of Pharmacology, Aristotle University of Thessaloniki, Greece
3 shared publications- Stavros A. Dimitrakos
2nd Department of Ophthalmology, Aristotle University of Thessaloniki, Greece
3 shared publications Nikolaos Georgiadis
1st Department of Ophthalmology, Aristotle University of Thessaloniki, Greece
2 shared publications
Latest Publications
- 1 November 2020
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 103 (6) , 913-914
Foveal involvement in a case of degenerative retinoschisis
- 1 November 2020
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 103 (6) , 913-914
Foveal involvement in a case of degenerative retinoschisis
- Open Access
- 19 June 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 430
Retinal and vitreous metastases from hepatocholangiocarcinoma
To report a case of metastatic hepatocholangiocarcinoma to the vitreous and retina. A 70-year-old male, who was recently diagnosed with hepatocholangiocarcinoma, was complaining of floaters in his right eye over the past 5 months and was referred to the Liverpool Ocular Oncology Centre. On presentation, his visual acuity in the right eye was 6/24. Fundus exam revealed a whitish, unilateral, full-thickness retinal lesion at the inferotemporal arcade of his right eye, with vitreous infiltration and subretinal fluid. The patient underwent 25G pars plana vitrectomy with biopsy, resection of the lesion and intravitreal bevacizumab injection. Histopathology testing of the surgical specimens confirmed the diagnosis of metastatic carcinoma to the eye. Two months postoperatively his visual acuity had improved to 6/7.5 and there was no sign of active disease in his right eye, while 9 months postoperatively his visual acuity decreased to 6/9.5 due to developing nuclear sclerotic cataract in his right eye. The current report presents the first case of a hepatocholangiocarcinoma metastasis to the vitreous and retina.
- 19 June 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 430
Open AccessRetinal and vitreous metastases from hepatocholangiocarcinoma
To report a case of metastatic hepatocholangiocarcinoma to the vitreous and retina. A 70-year-old male, who was recently diagnosed with hepatocholangiocarcinoma, was complaining of floaters in his right eye over the past 5 months and was referred to the Liverpool Ocular Oncology Centre. On presentation, his visual acuity in the right eye was 6/24. Fundus exam revealed a whitish, unilateral, full-thickness retinal lesion at the inferotemporal arcade of his right eye, with vitreous infiltration and subretinal fluid. The patient underwent 25G pars plana vitrectomy with biopsy, resection of the lesion and intravitreal bevacizumab injection. Histopathology testing of the surgical specimens confirmed the diagnosis of metastatic carcinoma to the eye. Two months postoperatively his visual acuity had improved to 6/7.5 and there was no sign of active disease in his right eye, while 9 months postoperatively his visual acuity decreased to 6/9.5 due to developing nuclear sclerotic cataract in his right eye. The current report presents the first case of a hepatocholangiocarcinoma metastasis to the vitreous and retina.
- 29 June 2016
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 31 (2) , 456-461
Physical activity and its correlation to diabetic retinopathy
- 29 June 2016
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 31 (2) , 456-461
Physical activity and its correlation to diabetic retinopathy
- Open Access
- 17 July 2014
- Published by Wiley in Journal of Diabetes Research
- Vol. 2014, 1-3
Diabetic Retinopathy Treated with Laser Photocoagulation and the Indirect Effect on Glycaemic Control
Purpose. To identify any possible relation between glycaemic control and previous laser photocoagulation for diabetic retinopathy.Methods. Seventy-two patients with diabetes were included in the study and were separated into 2 groups according to previous treatment (group A) or not (group B) with argon laser photocoagulation. Glycaemic control was estimated by measuring blood levels of HbA1c in four consecutive measurements.Results. Blood levels of HbA1c in group A were significantly lower 3, 6, and 12 months after laser treatment as compared to blood levels of HbA1c before laser treatment (% versus%,% versus%, and% versus%, resp., all). Blood levels of HbA1c in group B did not differ significantly in four consecutive measurements.Conclusion. Our results suggest that we should anticipate a better glycaemic control in cases of patients with diabetes previously treated with laser photocoagulation.- 17 July 2014
- Published by Wiley in Journal of Diabetes Research
- Vol. 2014, 1-3
Open AccessDiabetic Retinopathy Treated with Laser Photocoagulation and the Indirect Effect on Glycaemic Control
Purpose. To identify any possible relation between glycaemic control and previous laser photocoagulation for diabetic retinopathy.Methods. Seventy-two patients with diabetes were included in the study and were separated into 2 groups according to previous treatment (group A) or not (group B) with argon laser photocoagulation. Glycaemic control was estimated by measuring blood levels of HbA1c in four consecutive measurements.Results. Blood levels of HbA1c in group A were significantly lower 3, 6, and 12 months after laser treatment as compared to blood levels of HbA1c before laser treatment (% versus%,% versus%, and% versus%, resp., all). Blood levels of HbA1c in group B did not differ significantly in four consecutive measurements.Conclusion. Our results suggest that we should anticipate a better glycaemic control in cases of patients with diabetes previously treated with laser photocoagulation. - 4 July 2014
- Published by Springer Nature in Eye
- Vol. 28 (9) , 1136-1142
Multifocal electroretinogram contributes to differentiation of various clinical pictures within a family with Bardet–Biedl syndrome
To demonstrate the use of the multifocal electroretinogram (mfERG) in addition to the full-field electroretinogram (ERG) in defining varying clinical pictures in children within a family with Bardet-Biedl syndrome (BBS). All members from a family generation underwent a detailed history and examination before proceeding to a detailed ERG in accordance with the International Society of Clinical Electrophysiology for Vision protocol and a rapid, low-resolution mfERG. Of the sibling pair, the 13-year-old boy showed reduced vision and atypical maculopathy and the 10-year-old sister showed normal vision and atrophic maculopathy. Parents had normal ocular examination. The male sibling had reduced rod and cone full-field ERG responses with a relatively spared central response from the mfERG suggesting central macular sparing. In contrast, for the female sibling, the ERG was normal for the cone pathway although reduced for rod pathway, with mfERG showing central involvement. The mother had rod responses at the lower end of normal range, a normal cone pathway, and a normal mfERG. The father showed a normal ERG and mfERG. The mfERG is a useful adjunct to full-field ERG in the paediatric population and in family studies.
- 4 July 2014
- Published by Springer Nature in Eye
- Vol. 28 (9) , 1136-1142
Multifocal electroretinogram contributes to differentiation of various clinical pictures within a family with Bardet–Biedl syndrome
To demonstrate the use of the multifocal electroretinogram (mfERG) in addition to the full-field electroretinogram (ERG) in defining varying clinical pictures in children within a family with Bardet-Biedl syndrome (BBS). All members from a family generation underwent a detailed history and examination before proceeding to a detailed ERG in accordance with the International Society of Clinical Electrophysiology for Vision protocol and a rapid, low-resolution mfERG. Of the sibling pair, the 13-year-old boy showed reduced vision and atypical maculopathy and the 10-year-old sister showed normal vision and atrophic maculopathy. Parents had normal ocular examination. The male sibling had reduced rod and cone full-field ERG responses with a relatively spared central response from the mfERG suggesting central macular sparing. In contrast, for the female sibling, the ERG was normal for the cone pathway although reduced for rod pathway, with mfERG showing central involvement. The mother had rod responses at the lower end of normal range, a normal cone pathway, and a normal mfERG. The father showed a normal ERG and mfERG. The mfERG is a useful adjunct to full-field ERG in the paediatric population and in family studies.
- 13 June 2013
- Published by Springer Nature in International Ophthalmology
- Vol. 34 (3) , 613-621
Early diagnosis of Stargardt disease with multifocal electroretinogram in children
- 13 June 2013
- Published by Springer Nature in International Ophthalmology
- Vol. 34 (3) , 613-621
Early diagnosis of Stargardt disease with multifocal electroretinogram in children
- 1 January 2013
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 96 (1) , 109-111
Severe unilateral corneal melting after uneventful phacoemulsification cataract surgery
We present a rare case of severe unilateral corneal melt after uneventful phacoemulsification. A 38-year-old woman presented one week after uneventful phacoemulsification cataract surgery complaining of pain and blurred vision in her operated eye. Our differential diagnosis included peripheral ulcerative keratitis, Mooren's ulcer and herpetic keratitis. The patient was started on oral acyclovir and topical steroids. An extensive blood work-up was done to rule out autoimmune diseases. Purified protein derivative test demonstrated 15 mm of erythema. Because the clinical picture was progressing, the patient was started on triple anti-tuberculosis therapy. Despite treatment, the patient was complaining of excruciating eye pain that was relieved only with intramuscular prednisone injections. The corneal melt healed after approximately three months without any other intervention, leaving a 90 per cent thickness loss in its central area. Idiopathic corneal melt after uneventful phacoemulsification is a rare complication, which must be managed in a multidirectional treatment approach to prevent devastating corneal perforation.
- 1 January 2013
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 96 (1) , 109-111
Severe unilateral corneal melting after uneventful phacoemulsification cataract surgery
We present a rare case of severe unilateral corneal melt after uneventful phacoemulsification. A 38-year-old woman presented one week after uneventful phacoemulsification cataract surgery complaining of pain and blurred vision in her operated eye. Our differential diagnosis included peripheral ulcerative keratitis, Mooren's ulcer and herpetic keratitis. The patient was started on oral acyclovir and topical steroids. An extensive blood work-up was done to rule out autoimmune diseases. Purified protein derivative test demonstrated 15 mm of erythema. Because the clinical picture was progressing, the patient was started on triple anti-tuberculosis therapy. Despite treatment, the patient was complaining of excruciating eye pain that was relieved only with intramuscular prednisone injections. The corneal melt healed after approximately three months without any other intervention, leaving a 90 per cent thickness loss in its central area. Idiopathic corneal melt after uneventful phacoemulsification is a rare complication, which must be managed in a multidirectional treatment approach to prevent devastating corneal perforation.
- 1 May 2012
- Published by Wolters Kluwer Health in Cornea
- Vol. 31 (5) , 570-571
Bilateral Herpes Simplex Keratitis Presenting as Peripheral Ulcerative Keratitis
To report a case of bilateral Herpes simplex keratitis (HSK) masquerading as peripheral ulcerative keratitis (PUK). A case of a 47-year-old female complaining of painful red eyes with a history of arthritis and anterior uveitis attacks with positive antinuclear antibodies (ANA). Biomicroscopy revealed PUK, stromal infiltrations and bilateral central corneal epithelial erosions. Slit-lamp examination disclosed +3 anterior chamber cells in both eyes. Blood testing was positive for ANA. Herpes simplex virus (HSV) antigen was identified in both eyes using polymerase chain reaction (PCR). The management included topical prednisolone and acyclovir, as well as systemic valacyclovir. Improvement of epithelial corneal defects, PUK, and visual acuity was achieved gradually during the follow-up period. Bilateral herpetic keratitis presenting as PUK is an extremely rare manifestation of herpetic disease. PUK can pose a diagnostic dilemma in cases with immune system dysregulation. Excluding infectious agents is mandatory for appropriate treatment.
- 1 May 2012
- Published by Wolters Kluwer Health in Cornea
- Vol. 31 (5) , 570-571
Bilateral Herpes Simplex Keratitis Presenting as Peripheral Ulcerative Keratitis
To report a case of bilateral Herpes simplex keratitis (HSK) masquerading as peripheral ulcerative keratitis (PUK). A case of a 47-year-old female complaining of painful red eyes with a history of arthritis and anterior uveitis attacks with positive antinuclear antibodies (ANA). Biomicroscopy revealed PUK, stromal infiltrations and bilateral central corneal epithelial erosions. Slit-lamp examination disclosed +3 anterior chamber cells in both eyes. Blood testing was positive for ANA. Herpes simplex virus (HSV) antigen was identified in both eyes using polymerase chain reaction (PCR). The management included topical prednisolone and acyclovir, as well as systemic valacyclovir. Improvement of epithelial corneal defects, PUK, and visual acuity was achieved gradually during the follow-up period. Bilateral herpetic keratitis presenting as PUK is an extremely rare manifestation of herpetic disease. PUK can pose a diagnostic dilemma in cases with immune system dysregulation. Excluding infectious agents is mandatory for appropriate treatment.
- Open Access
- 19 November 2011
- Published by Wiley in Journal of Ophthalmology
- Vol. 2012, 1-12
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the neovascular AMD. Anti-VEGF agents are considered the most promising way of effectively inhibition of the neovascular AMD process. VEGF is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Two anti-VEGF agents have been approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD. Pegaptanib sodium, which is an aptamer and ranibizumab, which is a monoclonal antibody fragment. Another humanized monoclonal antibody is currently off-label used, bevacizumab. This paper aims to discuss in details the effectiveness, the efficacy and safety of these three anti-VEGF agents. New anti-VEGF compounds which are recently investigated for their clinical usage (VEGF-trap, small interfering RNA) are also discussed for their promising outcomes.
- 19 November 2011
- Published by Wiley in Journal of Ophthalmology
- Vol. 2012, 1-12
Open AccessAntivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the neovascular AMD. Anti-VEGF agents are considered the most promising way of effectively inhibition of the neovascular AMD process. VEGF is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Two anti-VEGF agents have been approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD. Pegaptanib sodium, which is an aptamer and ranibizumab, which is a monoclonal antibody fragment. Another humanized monoclonal antibody is currently off-label used, bevacizumab. This paper aims to discuss in details the effectiveness, the efficacy and safety of these three anti-VEGF agents. New anti-VEGF compounds which are recently investigated for their clinical usage (VEGF-trap, small interfering RNA) are also discussed for their promising outcomes.
- 18 April 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (3) , 248-254
Vitreous and serum levels of vascular endothelial growth factor and platelet‐derived growth factor and their correlation in patients with non‐proliferative diabetic retinopathy and clinically significant macula oedema
: Purpose: To investigate possible correlations between vitreous and/or serum levels of platelet‐derived growth factor isoforms (PDGF‐AA, ‐AB and ‐BB) with parameters associated with non‐proliferative diabetic retinopathy (NPDR) and clinically significant macula oedema (CSMO); to compare the results to relevant results regarding vascular endothelial growth factor (VEGF), which is an established growth factor affecting NPDR.Methods: Fifteen patients with NPDR, 31 patients with proliferative diabetic retinopathy (PDR) and 15 non‐diabetic patients were included in the study. Vitreous and serum samples were obtained during vitrectomy. PDGF‐AA, ‐AB and ‐BB, as well as VEGF, were measured by enzyme‐linked immunosorbent assay (ELISA).Results: PDGF‐AA, ‐AB and ‐BB and VEGF were all expressed in the serum and vitreous of controls and patients with NPDR. The levels of PDGF‐AA, PDGF‐AB and VEGF in vitreous were significantly increased in the NPDR group compared to controls, while PDGF‐BB levels were significantly decreased in the NPDR group compared to controls. The levels of all PDGF isoforms and VEGF in vitreous were significantly increased in the PDR group compared to the NPDR group. No such differences were evident in serum. PDGF‐AA and VEGF correlated significantly to the severity of NPDR. PDGF or VEGF in vitreous of NPDR patients did not correlate with retinal photocoagulation (RP) or the serum levels of haemoglobin A1c (HbA1c). There was no correlation between the vitreous and serum levels of VEGF or PDGF in patients with PDR. Only PDGF‐AB vitreous levels correlated significantly with PDGF‐BB vitreous levels in the NPDR group.Conclusion: It appears that in addition to VEGF, almost all PDGF isoforms in the vitreous are also correlated with NPDR and CSMO.
- 18 April 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (3) , 248-254
Vitreous and serum levels of vascular endothelial growth factor and platelet‐derived growth factor and their correlation in patients with non‐proliferative diabetic retinopathy and clinically significant macula oedema
: Purpose: To investigate possible correlations between vitreous and/or serum levels of platelet‐derived growth factor isoforms (PDGF‐AA, ‐AB and ‐BB) with parameters associated with non‐proliferative diabetic retinopathy (NPDR) and clinically significant macula oedema (CSMO); to compare the results to relevant results regarding vascular endothelial growth factor (VEGF), which is an established growth factor affecting NPDR.Methods: Fifteen patients with NPDR, 31 patients with proliferative diabetic retinopathy (PDR) and 15 non‐diabetic patients were included in the study. Vitreous and serum samples were obtained during vitrectomy. PDGF‐AA, ‐AB and ‐BB, as well as VEGF, were measured by enzyme‐linked immunosorbent assay (ELISA).Results: PDGF‐AA, ‐AB and ‐BB and VEGF were all expressed in the serum and vitreous of controls and patients with NPDR. The levels of PDGF‐AA, PDGF‐AB and VEGF in vitreous were significantly increased in the NPDR group compared to controls, while PDGF‐BB levels were significantly decreased in the NPDR group compared to controls. The levels of all PDGF isoforms and VEGF in vitreous were significantly increased in the PDR group compared to the NPDR group. No such differences were evident in serum. PDGF‐AA and VEGF correlated significantly to the severity of NPDR. PDGF or VEGF in vitreous of NPDR patients did not correlate with retinal photocoagulation (RP) or the serum levels of haemoglobin A1c (HbA1c). There was no correlation between the vitreous and serum levels of VEGF or PDGF in patients with PDR. Only PDGF‐AB vitreous levels correlated significantly with PDGF‐BB vitreous levels in the NPDR group.Conclusion: It appears that in addition to VEGF, almost all PDGF isoforms in the vitreous are also correlated with NPDR and CSMO.